Mattia Galli
@MattiaGalli10
MD, PhD | Interventional Cardiologist 🇮🇹 | Researcher 🇮🇹 🇺🇸 | Editor at EHJ-CVP 🇪🇺
ID:1199757789087850497
https://www.researchgate.net/profile/Mattia-Galli-2 27-11-2019 18:32:14
526 Tweets
2,8K Followers
1,4K Following
De-escalation and short DAPT strategies are both important approaches to reduce post-PCI bleeding in clinical practice. A new #PharmaPulse is now online in #EHJPharmacotherapy bit.ly/3TMccW4
Felice Gragnano EHJ-CVP Editor-in-Chief Mattia Galli Eliano Navarese Francesco Costa #DAPT
How should #anticoagulants and #antiplatelet therapy be used in different clinical settings? Expert perspective from Stefan Agewall in #EHJPharmacotherapy editorial👉 bit.ly/3PRhaQl
Felice Gragnano EHJ-CVP Editor-in-Chief Mattia Galli SABOURETCardiologist #coronary #PCI #afib2024
Use of #PPI is associated with ⬆️ risk of out-of-hospital cardiac arrest in the general population: data from a nationwide 🇩🇰 study now published in #EHJPharmacotherapy 👉 bit.ly/3Tn1HIB
Diego Segura-Rodríguez SABOURETCardiologist Felice Gragnano EHJ-CVP Editor-in-Chief #OHCA #heartattack
DAPA-MI did not show benefit of early initiation of #SGLT2i on #MACE or HHF in low-risk MI patients. Why the discordance? Read more in #EHJPharmacotherapy 👉
academic.oup.com/ehjcvp/article…
Mattia Galli Felice Gragnano DoreenTan.CVPx European Society of Cardiology Journals European Society of Cardiology
#postMI #HFhospitalisation
🫀 Switching from #DAPT to dual pathway inhibition in pts with chronic coronary syndrome: the SWAP-AC Study ⤵️
📖 DAPT associated with ⬆️ P2Y12 inhibition, DPI with ⬇️ thrombin generation
From TH current issue👉 thieme-connect.de/products/ejour…
#Platelets Luis Ortega Paz Mattia Galli
🔍A journey into the pleiotropic effects of ticagrelor in this elegant study exploring the effects of ticagrelor vs clopidogrel on ischemic preconditioning assessed by intracoronary-ECG: the TAPERS randomized study🎯bit.ly/3TeszdF
#EHJPharmacotherapy Ricky Turgeon PharmD
What is the best antithrombotic regimen after #TAVR ?
This updated network meta-analysis provides the comparative effects of different treatments🖥️ academic.oup.com/ehjcvp/advance…
Ricky Turgeon PharmD Arden Barry
#EHJPharmacotherapy #TAVI #Cardiox #cardiotwitter
The FLOW trial will shed light on the benefits of #semaglutide on the progression of renal impairment in pts with #T2DM and #CKD . A top-read #PharmaPulse article discusses the potential implications of this upcoming trial for practice: academic.oup.com/ehjcvp/article…
#EHJPharmacotherapy
Standard 12-month #DAPT is still the strategy of choice after #ACS
Should bleeding reduction strategies be the new standard of care? This #PharmaPulse explores Pros & Cons academic.oup.com/ehjcvp/advance…
Francesco Costa Eliano Navarese Mattia Galli
#EHJPharmacotherapy
#pharmacotherapy
📢 The clinical dilemma of #triglycerides in clinical practice: is #hypertriglyceridemia a worthy therapeutic target in #cardiovascular disease? 💊
academic.oup.com/ehjcvp/article…
Christopher Cannon, M.D. 🇺🇦 Maciej Banach Pierre Sabouret #EHJPharmacotherapy #Lipids #Cardiology #CardioTwitter
Have you read about the novel s.c. #furosemide formulation delivered by an abdominal patch infusion device in #HF ? One of the most read late-breaking science in #EHJPharmacotherapy academic.oup.com/ehjcvp/article…
Diego Segura-Rodríguez Giuseppe Galati Henry Han #heartfailure #pharmacotherapy
💥Net clinical benefit of extended dual pathway inhibition according to Baseline risk in patients with chronic coronary syndrome: a COMPASS substudy academic.oup.com/ehjcvp/article…
Felice Gragnano EHJ-CVP Editor-in-Chief Nikos Pyrpyris European Society of Cardiology Journals